

JUBILANT BIOSYS (SINGAPORE) PTE LTD

Balance Sheet

As at 31st Mar		Notes No	2015	2015	2014	2014
			USD	INR (' In Thousands)	USD	INR (' In Thousands)
I. EQUITY AND LIABILITIES						
Shareholders' Funds						
Share capital	1		1,371,501	68,559	1,371,501	68,559
Reserves & surplus	2		(74,344)	12,513	(61,175)	9,942
			1,297,157	81,072	1,310,326	78,502
Current liabilities						
Trade payables	3		13,848	865	4,722	283
Other current liabilities	4		159	10	159	10
			14,006	177	1,280	77
Total			1,311,163	81,948	1,315,207	78,794
II. ASSETS						
Non-current investments	5		1,306,552	81,660	1,306,552	78,276
Long-term loans and advances	6		3,636	227	3,971	238
			1,310,188	81,887	1,310,523	78,513
Current assets						
Cash & bank balances	7		975	61	4,683	281
			975	61	4,683	281
Total			1,311,163	81,948	1,315,207	78,794

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida

Date : 29th April, 2015

JUBILANT BIOSYS (SINGAPORE) PTE LTD

Statement of Profit and Loss

For the year ended 31st March,		2015	2015	2014	2014
Particulars	Notes No	USD	INR (' In Thousands)	USD	INR (' In Thousands)
EXPENSES					
Other expenses	8	12,834	784	11,806	713
Total expenses		12,834	784	11,806	713
Profit before exceptional item and tax		(12,834)	(784)	(11,806)	(713)
Exceptional Items	9	335	21	54	3
Profit for the year		(13,169)	(805)	(11,860)	(716)

Prakash C Bisht
 CFO (Ingredients) & Sr. VP (Group Accounts)
 Place : Noida
 Date : 29th April, 2015

JUBILANT BIOSYS (SINGAPORE) LIMITED

CASH FLOW STATEMENT

Cash flow Statement for the Year Ended	2015	2015	2014	2014
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
A. Cash flows from operating activities				
Net income before minority interest	(13,169)	(805)	(11,860)	(716)
Operating profit before working capital changes	(13,169)	(805)	(11,860)	(716)
Adjustments for :				
(Increase)/Decrease in trade and other receivables	335	20	54	3
Increase/(Decrease) in trade and other payables	9,125	558	(1,667)	(101)
Net cash inflow/(outflow) in course of operating activities	(3,709)	(227)	(13,473)	(814)
B. Cash flow arising from financing activities :				
Proceeds from issue of share capital(including share premium & net of share issue expenses)	-	-	15,000	906
Net cash inflow/(outflow) in course of financing activities	-	-	15,000	906
C. Foreign currency translation difference arising on consolidation				
		7		17
Net Increase in cash & cash equivalents (A+B+C)	(3,708)	(220)	1,527	109
Add: cash & cash equivalents at the beginning of year(including balance in dividend accounts)	4,683	281	3,156	171
Cash & cash equivalents at the close of the year(including balance in dividend accounts)	975	61	4,683	281

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in Accounting Standard 3 (AS-3)- "Cash Flow Statements"

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida

Date : 29th April, 2015

JUBILANT BIOSYS (SINGAPORE) PTE LTD
Notes to the Financial Statements

As at 31st Mar	2015	2015	2014	2014
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
1. SHARE CAPITAL				
Authorized				
Equity Share Capital	-	-	-	-
	-	-	-	-
Issued & Subscribed				
1,371,501 equity shares of USD 1 each	1,371,501	68,559.37	1,371,501	68,559
(Previous Year 1,371,501 equity shares of USD 1 each)	1,371,501	68,559.37	1,371,501	68,559
Paid up				
1,371,501 equity shares of USD 1 each	1,371,501	68,559.37	1,371,501	68,559
(Previous Year 1,371,501 equity shares of USD 1 each)	-	-	-	-
	1,371,501.00	68,559.37	1,371,501	68,559

1.1) The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share.

1.2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

3) The details of shareholders holding more than 5% shares in the company

As at 31st March	2015	2015	2014	2014
Name of the shareholder	USD	INR (' In Thousands)	USD	INR (' In Thousands)
Jubilant Biosys (BVI) LTD , BRITISH VIRGIN ISLANDS-The Holding Company	1,371,501	100.00%	1,371,501	100.00%

4) The reconciliation of the number of shares outstanding as at beginning and at the end of reporting period

As at 31st March	2015	2015	2014	2014
Name of the shareholder	No.	'INR (' In Thousands)	No.	'INR (' In Thousands)
Numbers of shares at the beginning	1,371,501.00	68,559	1,356,501.00	67,722
Add: Shares issued during the year	-	-	15,000.00	837
Numbers of shares at the end	1,371,501	68,559	1,371,501	68,559

5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

As at 31st March	2015	2015	2014	2014
Particulars	No.	'INR (' In Thousands)	No.	'INR (' In Thousands)
Jubilant Life Sciences (BVI) Ltd, British Virgin Islands-the Holding Company	1,371,501	68,559.37	1,371,501	68,559
1,371,501 equity shares of USD 1 each				

JUBILANT BIOSYS (SINGAPORE) PTE LTD
Notes to the Financial Statements

As at 31st Mar	2015	2015	2014	2014
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
2. RESERVES AND SURPLUS				
Foreign Currency Translation Reserve				
Foreign Currency Translation Reserve Opening	-	13,054.94	-	-
Foreign Currency Translation Reserve During the Year	-	3,375.73	-	13,054.94
	-	16,430.66	-	13,054.94
Surplus as per P&L Account				
As per last Balance Sheet	(61,175)	(3,113)	(49,315)	(2,396)
Add: Net Profit after tax transferred from Statement of Profit and Loss	(13,169)	(805)	(11,860)	(716)
	(74,344)	(3,918)	(61,175)	(3,113)
	(74,344)	12,513	(61,175)	9,942
3. TRADE PAYABLES				
Trade payables-others	13,848	865	4,722	283
	13,848	865	4,722	283
4. OTHER CURRENT LIABILITIES				
Other payables	159	10	159	10
	159	10	159	10
5. NON CURRENT INVESTMENTS				
Investment in Subsidiary/Fellow Subsidiaries Companies				
Jubilant Biosys LTD	1,306,552	81,660	1,306,552	78,276
295600 shares of USD 10 each				
	1,371,501	85,719	1,371,501	82,167
6. LONG TERM LOAN AND ADVANCES				
	3,636	227	3,971	238
	3,636	227	3,971	238
7. CASH AND BANK BALANCES				
Balances with banks:				
- On current accounts	975	61	4,683	281
	975	61	4,683	281
8. OTHER EXPENSE				
Auditors Remuneration - As Auditors	4,015.61	245.28	3,824.49	230.32
Legal , professional & consultancy charges	8,798.34	537.81	7,682.19	464.65
Director Sitting Fees	-	-	158.86	9.81
Bank Charges	20.00	1.20	140.00	8.43
	12,834	784	11,806	713
9. EXCEPTIONAL ITEMS				
Foreign Exchange Gain/Loss	335	21	54	3
	335	21	54	3